Phase I study evaluating the safety and efficacy of oral panobinostat in combination with radiotherapy or chemoradiotherapy in patients with inoperable stage III non-small-cell lung cancer
Authors:
- Nimit SinghalNSNimit Singhal
- Raghu GowdaRGRaghu Gowda
- Michael PennimentMPMichael Penniment
- Parineet TakharPTParineet Takhar
- Michael P. BrownMBMichael P. Brown
- 1 November 2015
- journal article
- Published by Wolters Kluwer Health in Anti-Cancer Drugs
- Vol. 26 (10) , 1069-1077
Abstract
Panobinostat is a radiosensitizing agent and targets the epigenetics of malignancy. This phase I study evaluated the safety and efficacy of combining oral panobinostat with radiotherapy (RT) or chemoradiotherapy (CRT) in patients with inoperable stage III non-small-cell lung cancer. This study had a parallel dose-escalating design combining oral panobinostat twice a week (dose escalations 20, 30, 45 mg) with either palliative RT (group A) or radical CRT (group B) using a standard chemotherapy protocol of cisplatin and etoposide. In group A (RT), nine recruited patients received treatment with oral panobinostat (doses 20, 30, 45 mg) with RT. Two serious adverse events, rapid atrial fibrillation and tracheo-oesophageal fistula, were not attributable to study treatment. The most common grade 3/4 toxicities were thrombocytopenia and lymphopenia, which resolved promptly after cessation of panobinostat. The disease control rate was 66%, the progression-free survival was 3 months and the median overall survival was 9 months. In group B (CRT), panobinostat dose was not escalated beyond 20 mg because of infection-related complications. Serious adverse events included opportunistic infection associated with treatment-related lymphopenia and febrile neutropenia without a source. One patient had cerebral infarct that was not attributed to study treatment. All patients achieved a partial response to treatment. At 33 months of follow-up, all patients were still alive. Panobinostat can be combined with palliative-dose RT at doses up to 45 mg twice a week with tolerable toxicity. Dose-limiting toxicities prevented the dose escalation of the panobinostat with CRT.Keywords
This publication has 23 references indexed in Scilit:
- A phase I study of oral panobinostat (LBH589) in Japanese patients with advanced solid tumorsInvestigational New Drugs, 2011
- Deciphering the molecular and biologic processes that mediate histone deacetylase inhibitor–induced thrombocytopeniaBlood, 2011
- Rational Therapeutic Combinations with Histone Deacetylase Inhibitors for the Treatment of CancerFuture Oncology, 2011
- Anaerobiospirillum succiniciproducens bacteraemia in a patient with acute lymphoblastic leukaemiaJournal of Medical Microbiology, 2009
- Phase III Study of Cisplatin, Etoposide, and Concurrent Chest Radiation With or Without Consolidation Docetaxel in Patients With Inoperable Stage III Non–Small-Cell Lung Cancer: The Hoosier Oncology Group and U.S. OncologyJournal of Clinical Oncology, 2008
- Acquired tracheo-oesophageal fistula in adultsContinuing Education in Anaesthesia Critical Care & Pain, 2006
- Modulation of cellular radiation responses by histone deacetylase inhibitorsOncogene, 2006
- Multimodality Therapy for Stage III Non–Small-Cell Lung CancerJournal of Clinical Oncology, 2005
- Hypofractionated Palliative Radiotherapy (17 Gy per two fractions) in Advanced Non–Small-Cell Lung Carcinoma Is Comparable to Standard Fractionation for Symptom Control and Survival: A National Phase III TrialJournal of Clinical Oncology, 2004
- Palliative radiation for stage 3 non-small cell lung cancer — A prospective study of two moderately high dose regimensLung Cancer, 1995